Mirvetuximab Soravtansine (IMGN853)
CAS: 1453084-37-1
Description:
Mirvetuximab soravtansine (IMGN853) is an antibody-drug conjugate (ADC) used to treat ovarian cancer. It combines an anti-folate receptor alpha (FRα) monoclonal antibody with the cytotoxic drug DM4, a derivative of maytansine. The antibody targets FRα, which is overexpressed on ovarian cancer cells, and delivers DM4 directly to the tumor. DM4 disrupts microtubules, causing cancer cell death. Mirvetuximab soravtansine is being studied for the treatment of FRα-positive ovarian cancer.
Key Features:
- FRα Targeting: The antibody specifically binds to FRα, a protein found on ovarian cancer cells, ensuring targeted delivery of the drug.
- Cytotoxic Agent (DM4): DM4 disrupts microtubules, leading to cancer cell death.
- Linker Technology: A stable linker ensures that DM4 reaches the target cancer cells, minimizing off-target effects.
Applications:
- Cancer Treatment: Targets and destroys FRα-positive ovarian cancer cells.
- Targeted Therapy: Delivers DM4 directly to the tumor, minimizing damage to healthy tissue.
- Monoclonal Antibody Therapy: Provides an effective treatment option for patients with FRα-positive ovarian cancer.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.